- Home
- GENI vs MESO Comparison
GENI vs MESO Comparison
Compare GENI & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENI
- MESO
- Stock Information
- Founded
- GENI 2016
- MESO 2004
- Country
- GENI United Kingdom
- MESO Australia
- Employees
- GENI N/A
- MESO N/A
- Industry
- GENI Services-Misc. Amusement & Recreation
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GENI Consumer Discretionary
- MESO Health Care
- Exchange
- GENI Nasdaq
- MESO Nasdaq
- Market Cap
- GENI 2.4B
- MESO 1.4B
- IPO Year
- GENI N/A
- MESO N/A
- Fundamental
- Price
- GENI $10.37
- MESO $10.97
- Analyst Decision
- GENI Strong Buy
- MESO Buy
- Analyst Count
- GENI 13
- MESO 4
- Target Price
- GENI $11.81
- MESO $18.00
- AVG Volume (30 Days)
- GENI 4.1M
- MESO 156.4K
- Earning Date
- GENI 05-06-2025
- MESO 02-26-2025
- Dividend Yield
- GENI N/A
- MESO N/A
- EPS Growth
- GENI N/A
- MESO N/A
- EPS
- GENI N/A
- MESO N/A
- Revenue
- GENI $535,167,000.00
- MESO $5,670,000.00
- Revenue This Year
- GENI $23.36
- MESO $152.37
- Revenue Next Year
- GENI $16.28
- MESO $336.12
- P/E Ratio
- GENI N/A
- MESO N/A
- Revenue Growth
- GENI 22.89
- MESO N/A
- 52 Week Low
- GENI $4.91
- MESO $5.78
- 52 Week High
- GENI $11.16
- MESO $22.00
- Technical
- Relative Strength Index (RSI)
- GENI 51.07
- MESO 44.34
- Support Level
- GENI $9.91
- MESO $10.77
- Resistance Level
- GENI $11.40
- MESO $11.61
- Average True Range (ATR)
- GENI 0.49
- MESO 0.47
- MACD
- GENI -0.07
- MESO 0.09
- Stochastic Oscillator
- GENI 50.48
- MESO 27.68
About GENI Genius Sports Limited
Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries. Its services are organized into three key product areas including Sports Technology and Services; Betting Technology, Content and Services; and Media Technology, Content and Services. All of its products are powered by proprietary technology and robust data infrastructure. It generates maximum revenue from the Betting Technology, Content and Services division. Geographically, the company derives a majority of its revenue from Europe.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.